Table 1.
Baseline characteristics of 61 patients with ST‐elevation myocardial infarction developing acute heart failure with or without cardiogenic shock
| Shock | Non‐shock | P value | |
|---|---|---|---|
| Total number (female/male) | 9 (3/6) | 52 (15/37) | 0.89 |
| Age (years, mean, and range) | 57 (49–68) | 66 (56–74) | 0.08 |
| TnTa (ng/L) | 14 640 (7580–20 925) | 12 279 (7811–16 607) | 0.43 |
| Creatininea (μmol/L) | 81 (52–150) | 82 (69–95) | 0.91 |
| eGFRa (mL/min/m2) | 60 (33–60) | 60 (60–60) | 0.24 |
| NT‐proBNPa (pmol/L) | 315 (202–721) | 463 (266–840) | 0.52 |
| C‐reactive proteina (mg/L) | 40 (24–100) | 57 (35–97) | 0.42 |
| WBC count (×109/L)a | 11 (8.9–17) | 12 (10–15) | 0.49 |
| IL‐6a (pg/mL) | 29 (19–40) | 27 (21–33) | 0.54 |
| Previous hypertension, n (%) | 5 (56) | 16 (31) | 0.15 |
| Previous dyslipidemia, n (%) | 1 (11) | 12 (23) | 0.42 |
| Current smoking, n (%) | 6 (67) | 16 (30) | <0.05 |
| Previous diabetes mellitus, n (%) | 1 (11) | 5 (10) | 0.89 |
| Previous statin treatment, n (%) | 2 (22) | 13 (25) | 0.86 |
| Previous myocardial infarction, n (%) | 3 (33) | 8 (15) | 0.20 |
| Multi‐vessel disease, n (%) | 5 (56) | 26 (44) | 0.76 |
| Atrial fibrillationa, n (%) | 1 (9) | 1 (2) | 0.16 |
| Systolic blood pressurea, mmHg | 85 (72–94) | 106 (96–117) | <0.001 |
| Diastolic blood pressurea, mmHg | 55 (48–58) | 67 (60–72) | <0.001 |
| Hours from symptom start to PCI | 3 (2–8) | 3 (2–6) | 0.80 |
| Hours from PCI to baseline | 17 (10–23) | 23 (14–32) | 0.07 |
| LVEFa, % | 44 (34–49) | 41 (38–47) | 0.88 |
| Antimicrobial treatment, n (%) | 8 (89) | 14 (27) | <0.001 |
| Mortality within 6 months, n (%) | 3 (33) | 2 (4) | <0.05 |
GFR, glomerular filtration rate; IL‐6, interleukin 6; LVEF, left ventricular ejection fraction; NT‐proBNP, N terminal pro brain natriuretic peptide; PCI, percutaneous coronary intervention; TnT, troponin T; WBC, white blood cell.
Data are given as median (25th and 75th percentile) or number (%).
a
At the time of inclusion, that is median 24 h following PCI.